Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 7/20 | 0.54 |
| ▸ | NOS3 | P29474 | 4/20 | 0.54 |
| ▸ | NOS2 | P35228 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL84394 | 0.82 | NOS3 (0.65) | NOS1NOS3NOS2KDM4EGAA | |
| SCHEMBL13324877 | 0.71 | HTR5A (0.39) | NOS1NOS3NOS2ALDH1A1CYP3A4 | |
| SCHEMBL2075410 | 0.70 | NOS3 (1.00) | NOS1NOS3NOS2KDM4ESIGMAR1 | |
| SCHEMBL20425672 | 0.70 | TLR8 (0.40) | NOS1NOS3NOS2TRPA1 | |
| SCHEMBL7506890 | 0.70 | NOS3 (0.38) | NOS1NOS3NOS2TRPA1 | |
| SCHEMBL5482045 | 0.69 | LMNA (0.58) | NOS1NOS3NOS2KDM4EGAA | |
| Hydrochloric Acid SCHEMBL8324907 | 0.69 | NOS3 (0.96) | NOS1NOS3NOS2SIGMAR1ALDH1A1 | |
| SCHEMBL22983115 | 0.67 | NOS3 (0.77) | NOS1NOS3NOS2SIGMAR1ALDH1A1 | |
| SCHEMBL4111485 | 0.67 | NOS2 (0.44) | NOS1NOS3NOS2KDM4EGAA | |
| SCHEMBL3030074 | 0.67 | OPRK1 (0.46) | NOS1NOS3NOS2GAASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498433-B2 | Process and intermediates for the preparation of olanzapine | KRKA, TOVARNA ZDRAVIL, D.D. (SI) | 2009-03-03 | — | — | US | disclosed |
| US-7498433-B2 | Process and intermediates for the preparation of olanzapine | KRKA, TOVARNA ZDRAVIL, D.D. (SI) | 2009-03-03 | — | — | US | disclosed |
| US-7498433-B2 | Process and intermediates for the preparation of olanzapine | KRKA, TOVARNA ZDRAVIL, D.D. (SI) | 2009-03-03 | — | — | US | disclosed |
| EP-1594879-B1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF OLANZAPINE | KRKA TOVARNA ZDRAVIL D D NOVO (SI) | 2008-10-22 | — | — | EP | disclosed |
| EP-1594879-B1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF OLANZAPINE | KRKA TOVARNA ZDRAVIL D D NOVO (SI) | 2008-10-22 | — | — | EP | disclosed |
| US-20060040921-A1 | Process and intermediates for the preparation of olanzapine | KRKA, TOVARNA ZDRAVIL D.D. (SI) | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040921-A1 | Process and intermediates for the preparation of olanzapine | CYP4F11, CYP4A11, CYP3A4 | NOS1 1899/4885NOS3 2748/4885NOS2 2786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.